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Clinical data and samples from patients diagnosed, more than 10 years previously, with operable node-negative breast cancer
(participants in the Scottish Adjuvant Tamoxifen trial), were revisited. Cases with two distinct categories of outcome were selected;
more than 10 years disease-free survival (‘good outcome’) or distant relapse within 6 years of diagnosis (‘poor outcome’). An initial
set of cases was analysed for a range of putative prognostic markers and a prognostic index, distinguishing the two outcome
categories, was calculated. This index was then validated by testing its predictive power on a second, independent set of cases. A
combination of histological grade plus immunochemical staining for BCL-2, p27 and Cyclin D1, generated a useful prognostic index
for tamoxifen-treated patients but not for those treated by surgery alone. The value of the index was confirmed in a second set of
tamoxifen-treated, early stage breast cancers. Overall, it correctly predicted good and poor outcome in 79 and 74% of cases,
respectively (odds ratio 11.0). Other markers assessed added little to prediction of outcome. In the case of molecular assays,
sensitivity and reliability were compromised by the age of the tissue specimens and the variability of fixation protocols. In selecting
patients for adjuvant systemic chemotherapy, the proposed index improves considerably on current international guidelines and
matches the performance reported for ‘gene-expression signature’ analysis.
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There is long-standing controversy over the management of small,
node-negative breast cancers. Surgical excision, with or without
local radiotherapy, plus adjuvant tamoxifen will result in long-
term disease-free survival for some 80% of patients. On the other
hand, around 20% will develop distant metastases and this figure
can be reduced by adjuvant chemotherapy (Early Breast Trialists,
1998). The issue is whether it is justifiable to expose all patients
with early disease to the side effects of cytotoxic therapy for the
benefit of the minority. If those at greatest risk of relapse could be
identified at the time of diagnosis, treatment decisions would be
simplified. Many attempts have been made to categorise patients
with operable node-negative tumours according to their individual
prognoses (Merkl and Osborne, 1989; Leonard, 1999; Isaacs et al,
2001; Mirza et al, 2002; Niu et al, 2002) but no single marker or
combination of markers has gained widespread acceptance and
authoritative guidelines achieve only very broad selection of
‘higher risk’ patients for adjuvant cytotoxic chemotherapy (Eifel
et al, 2001; Goldhirsch et al, 2001). Most recently, a prognostic
‘gene-expression signature’ has been described, based on micro-
array analysis of 70 genes (van’t Veer et al, 2002; van de Vijver et al,
2002). However, it will be some time before such sophisticated
technology can be applied in routine diagnostic practice (Schubert,
2003). Meanwhile, the range of possible predictive indicators,
identifiable by long-established techniques, continues to grow and
the potential benefits of a simple and reliable prognostic index
justify further assessment.
The natural history of breast cancer means that rigorous
evaluation of prognostic markers for ‘early’ disease requires
complete follow-up of substantial numbers of fully documented
patients over very long periods. The rarity of such databases
is a recognised limiting factor. However, the Scottish Adjuvant
Tamoxifen trial, which recruited patients with good prognosis
between 1980 and 1984, meets many of the necessary criteria
(Breast Cancer Trials Committee, 1987; Stewart et al, 2001).
In total, 751 of the patients studied had ‘operable’ disease,
defined as small (typically o2cm) mobile primary tumours with
no pathological involvement of axillary lymph nodes. All were
treated by mastectomy before randomisation to adjuvant tamox-
ifen for 5 years or to observation, with tamoxifen on first relapse.
Clinical and pathological findings were recorded in a standardised
fashion and follow-up has been meticulous, with outcome data
available on over 98% of the original entrants (Stewart et al, 2001).
Of these 751 patients, 16% considered potentially curable by
surgery alone, had suffered distant relapse within 6 years of
diagnosis.
The aim of the present study was to compare cases of operable
node-negative breast cancer, matched by time and place of
diagnosis and treatment, but differing by outcome, for a range of
putative prognostic markers and to derive empirically an index
that distinguished most accurately patients destined for long-term
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ydisease-free survival from those who would suffer early distant
relapse. That index would then be tested ‘prospectively’ on a
second, independent set of tumours for which the same outcome
data were available.
The tumour characteristics assessed included prognostic in-
dicators such as histopathological grade, tumour type and
oestrogen receptor alpha (ER), which are almost universally
applied, plus the following less well-established markers, chosen
on the basis of published reports.
By immunohistochemistry
Progesterone receptor (PgR) This is usually dependent on a
functioning oestrogen receptor, though there are exceptions. The
combination of ER and PgR may therefore provide better
prognostic discrimination than either on its own (Yoo et al,
1997; Yasui and Potter, 1999).
Cyclin D1 Although amplification of a region of chromosome 11
(q13) is a common finding in breast cancer and the most
consistently overexpressed oncogene from this region is Cyclin
D1, there is evidence that Cyclin D1 overexpression is a favourable
prognostic sign, associated with ER-positive, well-differentiated
tumours (Barnes and Gillett, 1998).
Ki67 The antigen expressed by this antibody is closely associated
with cell proliferation. Levels of Ki67 positivity have been
correlated with other features of aggressive tumour growth and
hence with poor prognosis (Forrest, 1997).
P27 This gene product is an inhibitor of cyclin-dependent
kinases and hence functions as a tumour suppressor. Barnes and
Gillett (1998) found some association between levels of Cyclin D1
and p27, both correlating with favourable outcome. Porter et al
(1997) confirmed that p27 expression correlated positively with
survival in young breast cancer patients.
BCL-2 The protein product of BCL-2 is located primarily within
the mitochondrial membrane and appears to function as an
inhibitor of cytochrome-C release, thus preventing initiation of
one apoptotic pathway. It is classified as an oncogene and was
initially identified as an important causal factor in certain B-cell
lymphomas. However, its role in breast cancer seems to be more
complex. While breast tumours expressing high levels of BCL-2 are
reported to show low rates of apoptotic cell death, they also have
low proliferation rates, low histopathological grades, absence of
p53 mutations and improved survival (Charpin et al, 1998; van
Slooten et al, 1998; Le et al, 1999).
Urokinase plasminogen activator (UPA) Digestion of the sur-
rounding tumour matrix by endogenous proteases may be an
important mechanism whereby carcinomas invade and metasta-
sise. UPA is one of the proteases linked to poor outcome in breast
cancer (Dano et al, 1985; Duffy et al, 1990; Bouchet et al, 1998).
By nuclear DNA content
Both aneuploidy and a high S-phase fraction have been recorded as
indicators of poor prognosis in early breast cancer, although the
latter may simply replicate the information available from
histological measurement of mitotic index or from immunohisto-
chemical markers of proliferation (Merkel and Osborne, 1989;
Bagwell et al, 2001).
By molecular analysis
Allele imbalance at specific loci, implying amplification or loss of
one copy of a particular DNA sequence has been correlated with
prognosis in a number of studies. Among the loci most
consistently implicated are 11q13, 13q12–13 and 17p13 (van de
Vijver, 1993; Devillee and Cornelisse, 1994).
MATERIALS AND METHODS
Case selection
Records of the Scottish Adjuvant Tamoxifen Trial were accessed
through the Cancer Intelligence Unit of the NHS (Scotland)
Common Services Agency in Edinburgh. For the initial (‘index-
generating’) data set, patients from both the Tamoxifen and the
control arms of the trial were included. Cases were classified as
‘good’ outcome if the patient had survived, without evidence of
disease, for at least 10 years and as ‘poor’ outcome if distant
metastases had been recorded within 6 years of diagnosis. To
enhance the power of the study, case selection was deliberately
biased towards the poor outcome group, who would otherwise
have formed less than 20% of the total series. The second
(‘validation test’) set of samples, comprised only patients who had
received adjuvant tamoxifen and, to avoid a shortfall in ‘poor’
outcome cases, those drawn from the Tamoxifen Trial series were
supplemented from two Scottish breast cancer centres (Victoria
Infirmary, Glasgow and Ninewells Hospital, Dundee) where data
had been recorded in uniform manner for over 10 years. ‘Good’
and ‘poor’ outcomes were defined as for the first series. There were
thus six subsets of patients, four in the initial series and two in the
second ‘test’ series (Table 1). Overall, 89 had remained disease-free
for more than 10 years, while 59 (40%) had developed distant
metastatic disease within 6 years of diagnosis.
Tissue samples and histology
Original tumour and lymph node blocks were located and
retrieved from hospital pathology departments. In a number of
instances, insufficient tumour material remained for the studies
proposed and, where possible, another case, from the same trial
arm and with the same outcome, was substituted. Fresh sections
were cut, mounted, stained with haematoxylin and eosin and re-
examined by a single specialist breast pathologist, who assessed
tumour type, histological grade (nuclear pleomorphism, mitotic
index and tubule formation), according to standard criteria
(Bloom and Richardson, 1957; Elston and Ellis, 1991). Degree of
Table 1 Breakdown of patient groups
Adjuvant tamoxifen No adjuvant tamoxifen
Good
outcome 23 25
First
set
Poor
outcome 21 14
Good
outcome 41
Second
(test) set
Poor
outcome 24
Subtotals Good outcome 64 25
Poor outcome 45 14
Total 109 39
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ynecrosis, vascular invasion and extent of lymphocyte infiltration
were also evaluated. Where different regions of the specimen
revealed tumour of differing grades, the highest grade was
recorded.
Immunohistochemistry
The primary antibodies used to demonstrate each of the listed
markers are shown in Table 2. All, except anti-Ki67 and anti-UPA,
are mouse monoclonal products.
Protocols were optimised for each antibody but, in general,
5mm sections of each tumour were mounted onto APES-coated
slides, dewaxed in Histocleart, immersed in 3% hydrogen
peroxide in methanol for 15min (to inhibit endogenous
peroxide activity) then exposed to ‘antigen-retrieval’ processing
(2 10min in a 750W microwave in citrate buffer pH 6).
Nonspecific antibody binding was blocked by 20min immersion
in normal goat serum (20% in PBS). Between treatments slides
were rinsed in water.
The relevant monoclonal or polyclonal primary antibody was
applied at the predetermined optimal concentration overnight at
room temperature. After rinsing, biotinylated F(ab)0
2 fragment of
goat anti-mouse Ig (goat anti-rabbit for polyclonal primary
antibodies) diluted 1:200 in PBS at pH 7.6 was applied for
30min at room temperature, followed by peroxidase-conjugated
streptavidin, diluted 1:300 in PBS, for 30min at room tempera-
ture. After a further rinse in PBS, peroxidase activity was detected
by incubating in freshly prepared Diaminobenzidine solution for
10min. Further rinses were followed by counterstaining with
haematoxylin. Sections were finally dehydrated, dried and
mounted for microscopic examination.
Results were recorded as the percentage of invasive cancer cells
showing specific staining. In general, all degrees of staining were
recorded but, where only overexpression was considered relevant,
positive scoring was restricted to those tumour cells showing
staining intensity above that of the adjacent benign epithelial cells.
To minimise subjectivity in this assessment, for BCL-2 assays,
two histopathologists scored each slide until training established a
high level of concordance between them. For p27 and Ki67, scoring
was undertaken by a single observer, repeating the analysis
without reference to the first result. Where there was greater that
10% discrepancy between the two results, reading was repeated
until a consistent score was obtained. For Ki67, the range of %
positive cells was low and a more accurate assessment was
considered necessary. A graticule was therefore used to identify
random high power ( 400) fields, within which counting
continued until a total of at least 200 tumour cells was achieved.
A positive control was included in each batch of staining, being a
section from a breast cancer known to stain strongly with the given
antibody. A negative control was stained along with each test
section and consisted of the adjacent section treated identically
except that no primary antibody was applied.
DNA content
Following published techniques (Hedley, 1989; Bagwell et al, 2001),
intact nuclei were extracted from 20mm sections of tumour after
trimming to remove adjacent nontumour tissue. Thick sections of
normal lymph node were used as sources of diploid nuclei for
reference. The DNA was stained with propidium iodide and
content recorded by flow cytometry on at least 10000 nuclei per
sample. The resulting histogram was analysed by a standard
FACScan program, which determined the percentage of diploid
cells, the percentage in S phase (‘S-phase fraction’) and the overall
DNA index (diploid, hypo- or hyperploid).
Molecular analysis
PCR amplification of microsatellites D11S534, D11S970, D13S267,
D13S171 and D17S1322 was undertaken on DNA extracted from
thin sections of fixed tissue (both tumour and normal lymph node
from the same patient), using a commercial extraction kit (Nuclear
Biosciences). PCR products were denatured and separated on an
8% polyacrylamide sequencing gel, transferred to a nylon
membrane and probed with a
32P-labelled (CA)22 oligonucleotide.
Signals were visualised by autoradiography and the relative
abundance of each allele in tumour and normal tissue compared
by eye.
Statistical methods
The associations of the individual histological, immunohistochem-
ical and molecular markers with outcome were examined by
comparing their values between the two outcome groups for the
first set of patients. Patients from the adjuvant tamoxifen and the
control arms of the trial were analysed separately.
For intrinsically categorical variables (tumour type, histological
grade) the w
2-test was used to assess associations with outcome,
and the categories grouped to identify the best categorisation for a
prognostic index.
For continuous variables (age, degree of necrosis, vascular
invasion, extent of lymphocyte infiltration, DNA content, ER, PgR,
UPA, Ki67, BCL-2, Cyclin-D1, p27), Student’s t-test was used in the
first instance to assess association. For those variables showing a
significant association with outcome, a range of thresholds for
categorising the patients was tried and the w
2 test used to choose
the best categorisation for prognosis.
The variables most strongly associated with outcome were
combined empirically to form a prognostic score. For each patient
the score was calculated and a threshold for good vs poor
prognosis was derived for each of the trial arms.
The scoring system was validated by applying it to the second
set of patients. The proportions of good and poor prognosis
patients correctly classified were calculated. The odds ratio for the
score between the good and poor outcome cases was calculated for
the adjuvant tamoxifen patients from first and second sets
combined.
Decision tree analysis (Venables and Ripley, 2002) was finally
applied to the whole data set as an additional independent test of
the findings. This stepwise approach splits the set of patients into
groups by every possible threshold value of every putative
prognostic factor, and chooses the split which results in the
maximum number of patients correctly classified. Next, the ‘best’
split is chosen for each of the two resulting subgroups. The process
is repeated until no further split can be found that results in
subgroups with different outcome. To avoid overfitting of the
model, which would generate an overoptimistic result, cross-
validation, by repeated holding-out of 10% of the patients, was
incorporated in the analysis. S-Plus statistical software was used.
Among the advantages of decision tree analysis over more
conventional approaches, such as logistic regression, are that (a) it
Table 2 Primary antibodies used in immunohistochemical analyses
Specificity Antibody
Oestrogen receptor Dako ID5 M7074
Progesterone receptor Novocastra NCL-PGR
Cyclin D1 Santa Cruz SC 6281
P27 Santa Cruz SC 1641
BCL-2 Dako M0887
Ki67 Dako A0047 (Rabbit polyclonal)
Urokinase From Dept of Chemical Pathology
plasminogen activator Academic Hospital, Nijmegen
(Rabbit polycloonal)
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with nonmonotonic relationships between the predictors and the
outcome, (b) subjects with missing data can be classified using the
data that are available for them, and (c) the results are intuitively
easy to interpret.
RESULTS
It was recognised that molecular analysis of samples fixed up to 20
years earlier and using various modifications of a standard
formalin-based protocol, would present difficulties. In the event,
analysable microsatellite products were generated from 58 to 74%
of samples, depending on the primers used. Heterozygosity rates
varied from 50 to 73% and allele imbalance in tumour tissue was
recorded in 23–37.5% of informative cases. Furthermore, for
individual informative tumours, there was measurable concor-
dance for allele imbalance between contiguous loci but not
between loci on different chromosome arms. These encouraging
results were, however, offset by the finding of what appeared to be
‘new’ alleles in a number of tumours. Since, in our experience, and
that of others, microsatellite instability is rare in breast cancers, we
suspected that the multiple (35) rounds of PCR amplification
required to obtain sufficient product from fixed tissue sections
were generating artefacts. This was confirmed in a formal
comparison of fixed and fresh tissue from the same source (Cohen
et al, 1998) and the problem was not resolved by varying technical
conditions or the type of polymerase used. Regretfully, therefore,
the molecular findings could not be used to derive a prognostic
index.
The ‘good outcome’ group were younger (mean age 53.0 years,
95% CI 50.01–55.99 vs mean age 57.7 years, 95% CI 54.24–61.25.
P¼0.044). The requirement for 10 years survival, in order to be
included in the ‘good’ prognosis category, probably contributed to
this effect.
Of the 83 tumours in the initial set, 13 were of ‘special’
pathological types (tubular or lobular) and there was no difference
in their distribution among subgroups. The presence of ductal (or,
in one instance, lobular) carcinoma in situ was correlated weakly
with good outcome (P¼0.03) and, while this association failed to
reach statistical significance for either arm of the trial, on its own,
it was stronger for the subgroup which had not received adjuvant
tamoxifen. As anticipated, ‘good’ and ‘poor’ outcome cases
differed on overall pathological grade, with 30% of the former,
but 54% of the latter, being grade 3 (P¼0.025). Unexpectedly, this
difference was accounted for entirely by cases from the adjuvant
tamoxifen arm of the trial, where the proportions of grade 3
tumours in the good and poor outcome group were 26 and 71%,
respectively (P¼0.003). No significant differences were found in
extent of vascular invasion, nor of tumour necrosis. Lymphocytic
infiltration was sparse or absent in the majority of cases. It was
substantial in only four tumours, all of which belonged to the
‘good outcome, no adjuvant tamoxifen’ category. However,
numbers were too small to justify incorporating this criterion
into a general prognostic index.
On DNA content analysis, good outcome tumours were more
often entirely diploid (46 vs 36.5%) but the difference was not
significant. Similarly, the distribution of hyper and hypodiploid
tumours showed no association with outcome. For cases showing
any degree of aneuploidy, there was a trend towards a higher
proportion of aneuploid cells among good prognosis tumours but,
again, this did not achieve significance. S-phase fractions, both for
the aneuploid and the diploid component of given tumours, varied
widely (2–50%) but neither correlated with prognostic group.
Among the immunohistochemical markers, oestrogen receptor
was more likely to be completely negative in the poor outcome
tumours (55 vs 41%) but the difference was nonsignificant.
Predictably, the difference was more marked for the groups who
had received adjuvant tamoxifen, where 44% of the good outcome,
but 67% of the poor outcome cases, had no detectable oestrogen
receptor (P¼0.04). Interestingly, the immunohistochemical re-
sults correlated poorly with the original records of ER level, which
had been determined by a dextran-coated charcoal exchange assay
(Breast Cancer Trials Committee, 1987), probably because the
earlier technique was highly sensitive to delay in sample
processing (R Leake, personal communication). Progesterone
receptor distribution was indistinguishable across the subgroups.
The same was true for UPA and Ki67 scores. Furthermore, 20% of
the Ki67 slides gave results considered to be technically
unsatisfactory, a problem that was not encountered with any of
the other antibodies.
Positivity for BCL-2 was clearly associated with a good outcome,
whether treating percentage of positive cells as a continuous
variable (P¼0.009) or taking a value of 45% of cells stained as the
boundary for a w
2-test (P¼0.01). The same trend was apparent for
Cyclin D1 and p27 staining but in neither case was there a
statistically significant result (P-values 0.06–0.15). For p27, the
association was restricted to the subgroup that had received
adjuvant tamoxifen and for Cyclin D1, the correlation was stronger
for the same subgroup.
Thus, of all the putative markers assessed, those that appeared,
individually, to merit further scrutiny, with a view to constructing
a prognostic index, were:
  Tumour grade.
  Presence of carcinoma in situ.
  Immunohistochemical staining for:
* BCL-2
* ER
* p27
* Cyclin D1.
Only BCL-2 staining and carcinoma in situ seemed promising
for patients who had not received adjuvant tamoxifen. In that
subgroup, the combination of low/negative BCL-2 (o30% cells
staining) and absence of carcinoma in situ was seen in 50% of
those with poor, but only 12.5% of those with good outcome.
Overall accuracy was 74% (odds ratio 7.0, P¼0.011). In terms of
outcome prediction, the combination was superior to either assay
on its own (odds ratios 2.95 and 3.5; P-values 0.13 and 0.08).
Given that each putative marker was being assessed for its
correlation with outcome in the same set of tumours, those
showing any prognostic potential were bound to correlate, to some
extent, with each other. It has already been shown, for example,
that overexpression of BCL-2 is strongly dependent on a
functioning ER (Le et al, 1999; Burow et al, 2000). Therefore, to
minimise the total number of variables comprising a prognostic
index for the subgroup who had received adjuvant tamoxifen, a
series of pairwise comparisons was undertaken to determine the
independent predictive value of each of the above six markers.
This demonstrated that pathological grade and BCL-2 staining
were the most powerful independent contributors to any
combination, while carcinoma in situ and oestrogen receptor
status added least information. Predictions based on tumour
grade, or immunohistochemical staining for BCL-2, p27 or cyclin
D1, all showed a useful measure of independence from each other.
A prognostic index was then derived by classifying the results
obtained for each of the four markers into three categories. These
are already specified for pathological tumour grade and, on
viewing the raw data for the others, the same cutoff values could be
assigned to them all, such that X70% positive staining ¼ ‘strong’,
31–69%¼ ‘moderate’ and p30% ¼ ‘weak’ (see Table 3).
Following the convention for pathological grading, a ‘strong’
result was assigned a numerical score of 1, a ‘moderate’ result, 2
and a ‘weak’ result, 3 (Figure 1). Adding these scores for all four
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yTable 3 Distribution of prognostic markers
Grade er % bcl2 % Cyclin D1 % p27 %
123 420 o20 470 31–69 o30 470 31–69 o30 470 31–69 o30
Tumour set 1 (On Tam) GOOD 11 6 6 11 11 7 4 12 8 6 9 8 3 10
P O O R 5 1 1 5 6 1 3311 6521 3231 2
Tumour set 1 (Not on Tam) GOOD 9 7 8 13 9 10 3 12 9 5 9 4 6 9
P O O R 6 4 4 85311 061 745 3
Tumour set 2 (On Tam) GOOD 20 11 9 31 10 15 5 21 33 1 7 21 5 15
P O O R 1 1 1 1 2 1 2 1 2151 8911 4641 4
TOTAL (On Tam only) GOOD 31 17 15 42 21 22 9 33 41 7 16 29 8 25
POOR 6 12 27 18 25 4 6 34 14 3 27 8 7 26
Figure 1 Photomicrographs illustrating ‘weak/negative’. Moderate and ‘strong’ staining for BCL-2, Cyclin D1 and p27. Note the positive staining of normal
duct epithelium in the Cyclin D1 ‘negative’ section.
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ymarkers produced an aggregate score of between 4 and 12 for any
given tumour.
The findings are summarised in Tables 3 and 4. As shown in
Table 4, an aggregate score X10 provided efficient discrimination
between poor and good outcome patients, correctly identifying 31
of 42 tumours (74%), for which all data were available (odds ratio
7.93, 95% CI 1.99, 31.59, P¼0.0021). For three patients (two good
outcome, one poor) a single value was missing from the set but
they were included in the analysis because substituting any score
(1, 2 or 3) for the missing one would not have brought the
aggregate to more than nine or less than 10, respectively. Varying
the weighting of the different parameters (e.g. increasing the
contribution of path grade and BCL-2, the two strongest individual
predictors of outcome) did not improve overall performance of the
index, nor did varying the cutoff values used to define ‘strong’,
‘moderate’ and ‘weak’ categories for any of the markers, nor did
adding further data, such as ER score or presence of carcinoma in
situ.
The test of any index derived from retrospective data must be to
apply it prospectively. In formal terms, we were able to do this by
‘blinding’ a second series of tumours. Because tamoxifen was used
very widely for early breast cancer in Scotland from the mid-1980s,
it was not possible to assemble sufficient unexposed, poor
outcome, cases to validate the index based on BCL-2 positivity
and presence of carcinoma in situ. However, 65 samples were
collected from patients with operable node-negative breast
cancers, diagnosed before 1990, who had received adjuvant
tamoxifen and had been followed up for at least 10 years or until
death. Overall, 41 had remained free from disease, while 24 had
suffered distant relapse within 6 years of diagnosis.
Fresh sections were cut and reassessed by the same specialist
breast pathologist. Immunohistochemical assays were carried out
and scored as before. On applying the prognostic index, derived as
above for the adjuvant tamoxifen group, it correctly identified 36
of the 40 (90%) ‘good’ outcome and 15 of the 24 (62.5%) ‘poor’
outcome tumours for which complete data were obtained, an
overall accuracy rate of 79.7% (odds ratio 15.0, 95% CI 4.0, 56.3,
P¼o0.0001) (Table 4).
Differences in performance of the index between the initial and
the ‘validation’ series of cases were not significant. Combining the
two data sets (Table 4c), 29 of 43 tumours (67.4%) that relapsed
early, and 53 of 63 (84.1%) that had not recurred after 10 years,
were correctly identified (overall accuracy 77.4%; odds ratio 11.0,
95% CI 4.3, 27.8, Po0.0001). The best of the individual predictive
markers (path grade 3 vs o3) had an overall accuracy of 69%
(odds ratio 4.7; P¼0.0002).
Cross-validated decision tree analysis was applied separately to
the 109 adjuvant tamoxifen patients and the 39 from the control
arm of the trial.
For the tamoxifen-treated group, the resulting decision tree is
shown as Figure 2. As 17 of the 109 patients had incomplete data,
only 92 patients were used to ‘grow’ the tree. The variables
included in this classification process are overall tumour grade,
Cyclin D1, p27 and BCL-2. This tree correctly classifies 79% of all
the patients; 95% of those with good outcome and 56% of those
with poor outcome (see Table 5).
For patients not receiving tamoxifen, numbers were smaller,
which affected the reliability of splits. Age was a useful predictor
(those over 45 had better prognosis), as were presence of
carcinoma in situ and BCL-2 score.
DISCUSSION
Features of the present study include substantial cohort size of
node-negative patients (particularly of those with poor outcome),
long and complete follow-up, consistent clinical management and
validation of initial findings, by ‘prospective’ application and by
independent ‘decision tree’ analysis. The latter statistical proce-
dure identifies essentially the same parameters contributing to
prediction of outcome and, although the information is handled
differently, the end results, in terms of prognostic accuracy, are
similar. The potential impact of the prognostic index on clinical
practice can be calculated as follows.
If 1000 patients with stage one breast cancer were treated by
surgery, local radiotherapy and tamoxifen alone, around 200 would
suffer distant relapse. These 200 should therefore be candidates for
systemic adjuvant chemotherapy. The proposed index would
identify 135 of them (67.4%), but would (wrongly) identify a
further 127 ‘cured’ patients as at high risk of relapse (15.9% of
800). On this basis, 262 (26.2%) of the 1000 patients would receive
cytotoxic drugs, just over half of them appropriately. Overall,
12.7% of the patients would be exposed needlessly to systemic
cytotoxic agents and 6.5% would ‘miss out’ on potentially
beneficial therapy. Applying the same analysis to predictions
based on gene expression signature, and considering only node-
negative patients (van de Vijver et al, 2002), 91.3% of those with
poor outcome would be correctly identified, but at the expense of
including 41.4% of those with good outcome. Thus, 514 of the 1000
cases would have received adjuvant chemotherapy. Of the 200
destined for early relapse, 183 would have been included. Reducing
the cutoff aggregate value for our prognostic index from 10 to 8
has the effect of identifying 86% of those with poor, but including
44% of those with good outcome. On that basis, we would give
adjuvant treatment to 524 of our notional 1000 patients and would
‘miss’ only 28 who actually require it.
None of these scenarios represents a perfect situation, but each
is, arguably, an advance on current NCI or St Gallen guidelines
(Eifel et al, 2001; Goldhirsch et al, 2001), both of which
recommend that adjuvant chemotherapy be given to the great
majority of ‘early’ breast cancer patients. Can our prognostic index
(or others) be improved? The selection of individual prognostic
markers is debatable. We chose not to include, for example, p53 or
HER2, both of which have been studied extensively, but which
have not been found consistently useful as independent predictors
of outcome in early breast cancer (Pharoah et al, 1999; Mirza et al,
Table 4 Performance of prognostic index in patients receiving adjuvant
tamoxifen
(a) First set Good outcome Poor outcome
Aggregate
Score o10 17 5
Aggregate
Score X10 6 14
(b) Second set Good outcome Poor outcome
Aggregate
Score o10 36 9
Aggregate
Score X10 4 15
(c) Combined sets Good outcome Poor outcome
Aggregate
Score o10 53 14
Aggregate
Score X10 10 29
Aggregate scores are derived from Path grade, plus extent of staining for BCL-2,
Cyclin D1 and p27, with individual scores of 1, 2 or 3 for each marker, as described in
the text.
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for node-positive cases (Sjogren et al, 1998; Pharoah et al, 1999)
Cyclin E, currently exciting much interest (Keyomarsi et al, 2002;
Loden et al, 2002), was, perhaps incorrectly, excluded on the
grounds that its expression was related to that of p27 (Porter et al,
1997). E-cadherin, c-myc and p21 are other markers not included
in this study that might be assessed as potential components of a
more refined prognostic index (Heimann et al, 2000; Schlotter et al,
2003; Winters et al, 2003). Several markers reported by others to be
of predictive value were not so in our hands. The fact that we were
dealing with tissues fixed in formalin (according to a variety of
protocols) up to 20 years earlier, accounts for the unreliability of
allele imbalance studies and may also have affected flow cytometry
analyses. Most positive results reported to date for UPA have relied
upon tumour cytosol protein extracts (Bouchet et al, 1998) so that
the immunohistochemical assay we applied is relatively untried. It
is not clear why Ki67 gave such disappointing results; however, a
recent review of prognostic factors in node-negative breast cancer
notes that ‘lack of standardisation in measurement techniques for
many of the markers, including Cathepsin D, Ki67, Her2/neu and
p53 limited their current usefulness’ (Mirza et al, 2002).
Any prognostic system must be tested and retested in different
centres, by different operators and on different patient cohorts
before it can be applied with confidence to clinical management. In
the course of such development, there is scope for addition, or
substitution of new markers. Those markers that did generate
predictive information from our archival specimens are, ipso facto,
likely to prove robust components of a prognostic panel for wider
application but others may prove superior.
It is almost inevitable that indicators of prognosis will be
influenced by treatment (Borg et al, 2003) since responses to both
hormonal and chemotherapy are affected by the biological
characteristics of a given tumour. Our finding that different
indices apply to patients in the tamoxifen and the control arms of
the trial is therefore no surprise and, in the strictest sense, our
index is predictive (of response to tamoxifen) rather than truly
prognostic. However, tamoxifen is now so widely used, and so well
tolerated, in early breast cancer that applicability of the index as a
prognostic tool is not seriously compromised.
The issue of predictive markers (i.e. identifying how individual
patients will respond to specific anticancer therapies) is important
but separate. For ‘early stage’ cancers it should arise only after
identification of the subset that will not do well on surgery and
tamoxifen alone. For those with nodal or distant spread, it is an
immediate concern on diagnosis. The recognition that breast
cancers are heterogeneous in terms of sensitivity to radiation and
to different drugs or drug combinations – and hence the ability to
‘tailor’ treatment to the individual patient – gives promise of major
therapeutic advances. Several molecular and immunohistochem-
Seven patients
Five good 
Two poor 
Overall grade = 1 or 2
Overall grade = 3
Cyclin D < 75 Cyclin D > 75
64% good 20% good 
BCL  5 BCL < 5 0% good
P27 < 55 P27  55
81% good
64% good
92 patients
59 good 
33 poor
38 patients 
31 patients
26 patients 
15 patients
12 poor 
Three good
11 patients
Seven good 
Four poor 
Five patients
Five poor 
Zero good
54 patients 
44 good 
10 poor 
Figure 2 Classification tree for tamoxifen-treated patients.
Table 5 Decision tree performance
Actual outcome
Good Poor
Predicted by Good 61 20
Decision tree Poor 3 25
Total 64 45
Odds ratio 25, 95% confidence interval (7, 93). This table refers to the decision tree
for tamoxifen-treated patients, shown in Figure 1. It incorporates the 17 patients
excluded from the tree growing because of missing data. Their predictions are based
on the data they do have. Misclassified cases are shown in bold.
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Fletcher, 1999; Lonning et al, 2001; Bertucci et al, 2002; Sotirou
et al, 2002; Chang et al, 2003; Egawa et al, 2003; Moliterni et al,
2003; Winters et al, 2003; Robson et al, 2004).
Gene expression microarray technology is also being applied to
prognosis in the same setting as the present study. It would
therefore be of great interest to compare ‘gene-expression signature’
(van de Vijver et al, 2002) with our index in comparable patient
groups. The two approaches appear to provide comparable levels of
sensitivity and specificity. Gene expression profiling has the
potential to provide rapid, comprehensive and relatively objective
information, but requires fresh tumour tissue and ‘high tec’
facilities, currently available in only one or two specialist centres
(Schubert, 2003). While the approach we have illustrated here may
be time-consuming and require experience to minimise subjectivity,
it can be applied in any diagnostic histology laboratory.
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